Date: October 19, 2022
Time: 10:00am (PDT), 1:00pm (EDT), 7:00pm (CEST)
In this webinar, we will introduce the generation and applications of Biocytogen’s severely immunodeficient (B-NDG) mice for preclinical research studies. B-NDG mice lack B, T, and NK cells, which makes them ideal recipients for the engraftment and study of human cells and tissues for oncology and immuno-oncology applications. In addition to introducing the parental strain, we will provide proof-of-concept data supporting the utility of two next-generation B-NDG models. For prolonged tumor studies, B-NDG mice have been further genetically modified to lack B2m microglobulin, which serves to delay the onset of graft-versus-host disease. In addition, B-NDG mice expressing human IL-15 can be employed for studies requiring survival and persistence of human NK cells. These models are robust in vivo preclinical platforms for the evaluation of novel anti-tumor drugs and immunotherapies, including cell therapies.
- Learn the application of immunodeficient mice for evaluating novel anti-tumor therapies.
- Understand the utility of B-NDG B2m KO mice to delay onset of graft-versus-host disease.
- Introduce the use of B-NDG hIL15 mice for evaluating anti-tumor activity of human NK cells.
Webinars will be available for unlimited on-demand viewing after live event.